



**Department of Vermont Health Access  
Pharmacy Benefits Management Program  
*DUR Board Meeting Agenda***

---

**May 14, 2013 6:00 – 8:30 p.m.**

- 1. Executive Session** **6:00 - 6:30**
  - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))
  
- 2. Introductions and Approval of DUR Board Minutes** **6:30 - 6:35**  
(Public Comment Prior to Board Action)
  
- 3. DVHA Pharmacy Administration Updates** **6:35 - 6:55**
  - Updates
  - Center for Evidence Based Policy Update
  - Psychotherapeutic Monitoring Quality Improvement Collaborative (PMQIC)
  
- 4. Medical Director Update** **6:55 - 6:55**
  - Clinical Programs Update
  - Prescriber Comments
  
- 5. Follow-up Items from Previous Meetings** **6:55 - 7:15**
  - Methadone for Chronic Pain
  - Suboxone<sup>®</sup> Tablet to Film transition
  
- 6. RetroDUR/DUR** **7:15 – 7:25**
  - Second Reconsiderations by Medical Director
  - Xyrem<sup>®</sup> (sodium oxybate)
  
- 7. Clinical Update: Drug Reviews** **7:25 – 7:45**  
(Public comment prior to Board action)
  - Abbreviated New Drug Reviews**
    - Delzicol (mesalamine delayed release) Oral Capsule
    - Xyrem<sup>®</sup> (sodium oxybate) Oral Solution
  
  - Full New Drug Reviews**
    - Aubagio<sup>®</sup> (teriflunomide) Oral Tablet
    - Linzess<sup>®</sup> (linaclotide) Oral Capsule

**8. Therapeutic Drug Classes – Periodic Review** **7:45 – 8:15**

(Public comment prior to Board action)

**Class review documents available on DVHA web site 05/14/2013 @ 12 Noon**

- Anti-diabetics: Oral
  - Alpha Glucosidase Inhibitors
  - Biguanides
  - Dipeptidyl Peptidase (DPP-4) Inhibitors
  - Meglitinides
  - Sulfonylureas
  - Thiazolidinediones
- Anti-diabetics: Injectable:
  - Incretin Mimetics & Amylinomimetics
  - Insulin
- Anti-infectives: Antibiotics:
  - Cephalosporins - 1<sup>st</sup> Generation
  - Cephalosporins - 3<sup>rd</sup> Generation
  - Macrolides and Ketolides
- Constipation: Chronic, IBS-C or Opioid Induced
- Phosphodiesterase-4 Inhibitors
- Pulmonary:
  - Beta Agonists and Anticholinergic Combinations
- Smoking Cessation Agents

**9. New Managed Therapeutic Drug Classes** **8:15 – 8:15**

(Public comment prior to Board action)

- None

**10. Review of Newly-Developed/Revised** **8:15 – 8:25**

**Clinical Coverage Criteria and/or Preferred Products**

(Public comment prior to Board action)

- Pediatric Antipsychotic Medications

**11. General Announcements** **8:25– 8:30**

**Selected FDA Safety Alerts**

- Potiga (Ezogabine): Drug Safety Communication - Linked To Retinal Abnormalities And Blue Skin Discoloration
- Samsca (Tolvaptan): Drug Safety Communication - FDA Limits Duration and Usage Due To Possible Liver Injury Leading to Organ Transplant or Death
- Valproate Anti-Seizure Products: Drug Safety Communication - Contraindicated for Pregnant Women for Prevention of Migraine Headaches

**12. Adjourn** **8:30**